MESO vs ANIK

For growth investors, Mesoblast Limited (MESO) is the stronger pick with 191.

4% revenue growth year-over-year, versus -5. 9% for Anika Therapeutics, Inc. (ANIK). Analysts rate Mesoblast Limited (MESO) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Mesoblast Limited (MESO) delivered a total return of +6.

0%, compared to -63. 9% for Anika Therapeutics, Inc. (ANIK). Over 10 years, the gap is even starker: MESO returned -2. 1% versus ANIK's -65. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Anika Therapeutics, Inc.

(ANIK) is the lower-risk stock at 1. 14β versus Mesoblast Limited's 1. 70β — meaning MESO is approximately 48% more volatile than ANIK relative to the S&P 500. On balance sheet safety, Anika Therapeutics, Inc. (ANIK) carries a lower debt/equity ratio of 17% versus 21% for Mesoblast Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Mesoblast Limited (MESO) is pulling ahead at 191.

4% versus -5. 9% for Anika Therapeutics, Inc. (ANIK). On earnings-per-share growth, the picture is similar: Anika Therapeutics, Inc. grew EPS 80. 2% year-over-year, compared to 5. 6% for Mesoblast Limited. Over a 3-year CAGR, MESO leads at 19. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Anika Therapeutics, Inc.

(ANIK) is the more profitable company, earning -9. 6% net margin versus -593. 9% for Mesoblast Limited — meaning it keeps -9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANIK leads at -9. 8% versus -363. 1% for MESO. At the gross margin level — before operating expenses — MESO leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Anika Therapeutics, Inc.

(ANIK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 14)). Mesoblast Limited (MESO) carries a higher beta of 1. 70 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ANIK: -65. 9%, MESO: -2. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MESO is a small-cap high-growth stock; ANIK is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.